opioid sparing analgesia post-thoracotomy

Preemptive subcutaneous nalbuphine for Opioid sparing analgesia after thoracotomy: A prospective Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202104609519383

Enrollment

Registered

2021-04-12

Start date

2021-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery Anaesthesia

Interventions

placebo

nalbuphine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients of both sex, American Society of Anesthesiologists (ASA) physical status I, II and III, aged 20 to 80 years selected for open thoracic surgery

Exclusion criteria

Exclusion criteria: Patients with allergy to nalbuphine or morphine; opioid abuse, history of chronic pain, recurrent operation, pregnancy; uncontrolled hepatic or renal diseases; neurologic or psychiatric illnesses that would interfere with assessment of pain score

Design outcomes

Primary

Measure	Time frame
postoperative consumptions of morphine	—

Secondary

Measure	Time frame
The intraoperative consumptions of fentanyl;Time to first dose of opioid analgesia postoperative ;acute pain assessment;chronic pain assessment;Length of hospital stay;The incidence of postoperative opioid-related adverse events	—

Countries

Egypt

Contacts

Public ContactMona Elghamry

lecturer

drmonagh19802000@gmail.com+201060101867

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026